Cargando…

Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma

Surgical resection remains a first-line therapy for glioblastoma multiforme (GBM). Increased extent of resection (EOR) of noncontrast-enhancing regions in T2-weighted MRI images (T2-EOR) provides a survival benefit for GBM patients receiving standard radio/chemotherapy. However, whether it also impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Xiaohan, Wang, Yi, Li, Chunzhao, Huang, Xijian, Gao, Hua, Zhang, Yang, Ji, Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158124/ https://www.ncbi.nlm.nih.gov/pubmed/35664765 http://dx.doi.org/10.3389/fonc.2022.877190

Ejemplares similares

Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination
por: Wang, Yi, et al.
Publicado: (2022)

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
por: Eton, Omar, et al.
Publicado: (2010)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

A Nomogram Predicts Individual Prognosis in Patients With Newly Diagnosed Glioblastoma by Integrating the Extent of Resection of Non-Enhancing Tumors
por: Zhang, Zhe, et al.
Publicado: (2020)

Immunotherapy with heat shock protein 96 to treat gliomas
por: Li, Chunzhao, et al.
Publicado: (2020)

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage
por: Cui, Xiaoteng, et al.
Publicado: (2021)

New Immunotherapeutic Approaches for Glioblastoma
por: Vázquez Cervantes, Gustavo Ignacio, et al.
Publicado: (2021)

Immunotherapeutic Approaches for Glioblastoma Treatment
por: Yaghi, Nasser K., et al.
Publicado: (2022)

Intrasession Reliability of Arterial Spin-Labeled MRI–Measured Noncontrast Perfusion in Glioblastoma at 3 T
por: Zhou, Limin, et al.
Publicado: (2020)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Experiences and Expectations for Glioma Immunotherapeutic Approaches
por: Yamanaka, Ryuya, et al.
Publicado: (2014)

Immunotherapeutic Potential of T Memory Stem Cells
por: Li, Yujie, et al.
Publicado: (2021)

Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment
por: Kaimala, Suneesh, et al.
Publicado: (2018)

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
por: Meyers, Daniel E., et al.
Publicado: (2017)

Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
por: Dapash, Mark, et al.
Publicado: (2021)

Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
por: Niedbała, Marcin, et al.
Publicado: (2022)

Prognosis was not deteriorated by multiple primary cancers in esophageal cancer patients treated by radiotherapy
por: Shirai, Katsuyuki, et al.
Publicado: (2013)

gp96 Expression in Gliomas and Its Association with Tumor Malignancy and T Cell Infiltrating Level
por: Li, Chunzhao, et al.
Publicado: (2022)

Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC
por: He, Ping, et al.
Publicado: (2023)

Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
por: Piper, Keenan, et al.
Publicado: (2021)

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
por: Perutelli, Francesca, et al.
Publicado: (2022)

Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase–Mutant Glioblastoma: A Multicenter Study
por: Uetani, Hiroyuki, et al.
Publicado: (2023)

Efficacy of Location-Based Features for Survival Prediction of Patients With Glioblastoma Depending on Resection Status
por: Soltani, Madjid, et al.
Publicado: (2021)

Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy
por: Chen, Shanshan, et al.
Publicado: (2023)

Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
por: Ortiz, Michael V., et al.
Publicado: (2019)

T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?
por: Zhou, Qi, et al.
Publicado: (2020)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma
por: Zhang, Keying, et al.
Publicado: (2021)

Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer
por: Hirani, Priyanka, et al.
Publicado: (2021)

The role of CMV in glioblastoma and implications for immunotherapeutic strategies
por: Rahman, Maryam, et al.
Publicado: (2018)

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
por: Nesseler, Jean Philippe, et al.
Publicado: (2018)

Efficacy of Whole-Ventricular Radiotherapy in Patients Undergoing Maximal Tumor Resection for Glioblastomas Involving the Ventricle
por: Kim, Kyung Hwan, et al.
Publicado: (2021)

Erratum: Efficacy of Location-Based Features for Survival Prediction of Patients With Glioblastoma Depending on Resection Status
Publicado: (2021)

Subtotal Resection of a Thalamic Glioblastoma Multiforme through Transsylvian Approach
por: Motiei-Langroudi, Rouzbeh, et al.
Publicado: (2017)

Complete and Incomplete Resection for Progressive Glioblastoma Prolongs Post-Progression Survival
por: Behling, Felix, et al.
Publicado: (2022)

Radiomics Analysis on Noncontrast CT for Distinguishing Hepatic Hemangioma (HH) and Hepatocellular Carcinoma (HCC)
por: Hu, Shuyi, et al.
Publicado: (2022)

Identification and Validation of Immune-Related Long Non-Coding RNA Signature for Predicting Immunotherapeutic Response and Prognosis in NSCLC Patients Treated With Immunotherapy
por: Ma, Jianli, et al.
Publicado: (2022)

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014)

Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

Cuproplasia characterization in colon cancer assists to predict prognosis and immunotherapeutic response
por: Zhang, Bomiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lm9msb9ibhm9n1cehrkb5f8t03